Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth-Ayerst/Elan Naprelan label includes data suggesting reduced GI side effects, but no explicit claim.

Executive Summary

WYETH-AYERST/ELAN NAPRELAN PHARMACY AVAILABILITY SET FOR APRIL following FDA's Jan. 5 approval of the once-daily version of naproxen sodium. The new formulation employs Elan's IPDAS system to deliver the nonsteroidal anti-inflammatory drug naproxen, the active ingredient in Roche's Naprosyn/Anaprox. Wyeth-Ayerst will market the drug under a July agreement with Elan. The naproxen ingredient accounts for about 20% of NSAID prescriptions, the firms said.
UsernamePublicRestriction

Register

PS027500

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel